Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Recruiting

Phase 3

TelitaciceptPhase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Sponsor:

Vor Biopharma

Code:

NCT07404865

Conditions

Primary Sjogren's Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Telitacicept

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-21. This information was provided to ClinicalTrials.gov by Vor Biopharma on 2026-05-19.